Herantis Pharma releases 1H 2025 report today

Core Viewpoint - Herantis Pharma is making significant clinical progress with its lead product HER-096, which is in the Phase 1b study for Parkinson's disease, with key data expected by mid-October 2025 [2][10]. Business Highlights January – June 2025 - The company reported other operating income of EUR 135,000, a decrease from EUR 987,000 in 1H 2024 [6]. - Payroll and related expenses increased to EUR 1,115,000 from EUR 766,000 in 1H 2024 [6]. - Other operating expenses decreased to EUR 1,975,000 from EUR 2,977,000 in 1H 2024 [6]. - The loss for the period was EUR 3,201,000, compared to a loss of EUR 2,687,000 in 1H 2024 [6]. - Cash flow from operating activities was negative EUR 3,388,000, slightly worse than negative EUR 3,035,000 in 1H 2024 [6]. - The equity ratio decreased to 34.2% from 55.9% in 1H 2024 [6]. - The number of shares at the end of the period increased to 24,094,817 from 20,160,733 in 1H 2024 [6]. Key Clinical Developments - HER-096 has shown encouraging pharmacokinetic data in healthy volunteers and has advanced through the Phase 1b trial, with the last patient visit completed on August 14, 2025 [2][5][10]. - The first patient with Parkinson's disease was dosed in the Phase 1b study at the end of January 2025 [8]. - A directed share issue raised EUR 5.2 million in February 2025, strengthening the company's financial position for the Phase 1b readout [11]. - The final cohort of the Phase 1b trial evaluated the safety and tolerability of 300 mg doses of HER-096 versus placebo in patients with Parkinson's disease [8]. Future Outlook - The company is focused on analyzing data from the Phase 1b study and expects to present topline data by mid-October 2025, with full data readout anticipated before the end of the year [12]. - Preparations for the Phase 2 study of HER-096 are ongoing, guided by the full Phase 1b dataset expected later this year [2][12].